SCHEMBL2978401

SCHEMBL2978401

CCS(=O)(=O)c1nnnn1-c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 15/20 0.71
MAPT P10636 9/20 0.71
LMNA P02545 7/20 0.64
HTT P42858 7/20 0.64
TP53 P04637 5/20 0.64
NPSR1 Q6W5P4 5/20 0.64
HPGD P15428 5/20 0.64
HSD17B10 Q99714 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
KMT2A Q03164 4/20 0.55
S1PR4 O95977 2/20 0.55
S1PR1 P21453 2/20 0.55
RAB9A P51151 2/20 0.55
MAPK1 P28482 2/20 0.55
TSHR P16473 2/20 0.47
MEN1 O00255 2/20 0.47
PTGS2 P35354 1/20 0.47
GFER P55789 1/20 0.46
ALOX15 P16050 1/20 0.46
POLB P06746 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2976178 0.89 ALDH1A1 (0.69) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL2966537 0.86 ALDH1A1 (0.64) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL31642640 0.85 ALDH1A1 (0.69) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL17511740 0.85 ALDH1A1 (0.63) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL21482708 0.84 ALDH1A1 (0.64) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL1980247 0.84 ALDH1A1 (0.61) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL28102527 0.84 ALDH1A1 (0.61) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL16218976 0.84 ALDH1A1 (0.61) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL8177086 0.83 ALDH1A1 (1.00) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL12443641 0.82 MAPT (0.69) ALDH1A1MAPTLMNAHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
CN-112811994-B Difluoro ether compound with 3-pentenyl end group and synthesis method thereof 江苏和成新材料有限公司 2024-02-02 CN disclosed
CN-109071424-B Sulfamate derivative compound, preparation method and application thereof 生物药品解决方案有限公司 2022-01-14 CN disclosed
CN-112811994-A Difluoro ether compound with end group of 3-pentenyl and synthesis method thereof 江苏和成新材料有限公司 2021-05-18 CN disclosed
US-20210115044-A1 TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-04-22 US disclosed
EP-3784241-A1 TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck Sharp&Dohme Corp. (US) 2021-03-03 EP disclosed
CN-112088005-A Tricyclic heterocyclic compounds useful as HIV integrase inhibitors 默沙东公司 2020-12-15 CN disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
EP-3423433-A1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES Bio-Pharm Solutions Co., Ltd. (KR) 2019-01-09 EP disclosed
EP-1521752-B1 MACROCYCLES FOR THE TREATMENT OF CANCER BIOTECHNOLOG FORSCHUNG GMBH (DE) 2009-02-25 EP disclosed
EP-1521752-B1 MACROCYCLES FOR THE TREATMENT OF CANCER BIOTECHNOLOG FORSCHUNG GMBH (DE) 2009-02-25 EP disclosed
CN-101203483-A N-substituted phenylacetamide derivatives and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO (JP) 2008-06-18 CN disclosed
EP-1884510-A1 N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-02-06 EP disclosed
US-20060128966-A1 Thia-epothilone derivatives for the treatment of cancer MORPHONCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2006-06-15 US disclosed
US-20060004065-A1 Novel macrocycles for the treatment of cancer WOLFGANG RICHTER (DE) 2006-01-05 US disclosed
EP-1567524-A1 THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER Richter, Wolfgang (DE) 2005-08-31 EP disclosed
EP-1521752-A1 NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER Gesellschaft fur Biotechnologische Forschung mbH (gbf) (DE) 2005-04-13 EP disclosed
WO-2004048372-A1 THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER MORPHOCHEM AG KOMB CHEMIE (DE) 2004-06-10 WO disclosed
WO-2004007492-A1 NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER GESELLSCHAFT FUER BIOTECHNOLGISCHE FORSCHUNG MBH (GBF) (DE) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128966-A1 Thia-epothilone derivatives for the treatment of cancer TTPA, THPO, TERT ALDH1A1 190/4885MAPT 4190/4885LMNA 3897/4885
US-20210115044-A1 TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS TYMP, CCNI, TYMS ALDH1A1 706/4885MAPT 3652/4885LMNA 2148/4885
US-20060004065-A1 Novel macrocycles for the treatment of cancer CCNI, CCNB1, CCNC ALDH1A1 1428/4885MAPT 4152/4885LMNA 2796/4885
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses STS, SULT2A1, SULT1A1 ALDH1A1 844/4885MAPT 379/4885LMNA 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.